Introduction
Transforming growth factor-b (TGF-b) potently inhibits the proliferation of many cell types (Alexandrow and Moses, 1995; Roberts and Sporn, 1993) . It suppresses formation of a variety of epithelial tumors and many tumor cells eventually become refractory to growth inhibition by TGF-b (Fynan and Reiss, 1993; Markowitz et al., 1995; Massague, 1998) . TGF-b signals via two receptor Ser/Thr protein kinases, termed type I and type II TGF-b receptors. The type II receptor phosphorylates and activates the type I receptor, which then phosphorylates Smad2 or Smad3 within their C-terminal Ser-Ser-X-Ser motifs. Once activated, Smad2 or Smad3 associate with the shared signaling molecule Smad4, translocate to the nucleus and in concert with additional transcription factors alters the transcription of a large repertoire of genes (Massague, 1998; Piek et al., 1999) . Induction of growth arrest by TGF-b occurs via interference with cell cycle progression. Progression from G 1 to S phase involves initial phosphorylation of the retinoblastoma tumor suppressor protein (pRb) by cyclin D complexed with the cyclin-dependent kinases 4 or 6 (CDK4/6) (Harbour et al., 1999) . The ensuing hyperphosphorylation by cyclin E-CDK2 releases E2F transcription regulators from pRb; the released E2F then transactivates cyclin E and other genes (Sherr and Roberts, 1999) . Cyclin E-CDK2 activity is essential for G 1 to S transition. Because cyclin E is induced in response to E2F, this generates a positive feedback loop promoting pRb phosphorylation, E2F release and CDK2 activation (Sherr and Roberts, 1999) . With dependence on the cell type, TGF-b inhibits the proliferation of epithelial cells by suppressing the expression of cMyc, cyclin A and CDK4/6 (Ewen et al., 1993; Pietenpol et al., 1990; Tsubari et al., 1999; Warner et al., 1999) , and by inducing the CDK4/6-speci®c inhibitor p15
Ink4B (p15) (Hannon and Beach, 1994) . p15 releases p27
Kip1 (p27) from CDK4/6, enabling it to bind to CDK2 and inhibit its activity (Polyak et al., 1994; Reynisdottir and Massague, 1997; Sherr and Roberts, 1999; Tsubari et al., 1999) . These events correlate with cell cycle arrest.
TGF-b resistance can be acquired through mutational inactivation of TGF-b receptors (DeCoteau et al., 1997; Inagaki et al., 1993; Kimchi et al., 1988; Markowitz et al., 1995; Schiemann et al., 1999) or Smad proteins (Massague, 1998; Piek et al., 1999) , disruption of Smad function by oncoproteins such as Ski and Evi-1 (Kurokawa et al., 1998; Luo et al., 1999; Sun et al., 1999b) , or release of p27-mediated CDK2 inhibition by viral oncogenes (Mal et al., 1996) . Oncogenic H-Ras V12 also abrogates TGF-b signaling (Filmus et al., 1992; Houck et al., 1989; Kretzschmar et al., 1999; Longstreet et al., 1992; Oft et al., 1996; Schwarz et al., 1988; Valverius et al., 1989) . It was suggested that this occurs by MAP kinase-dependent phosphorylation of Smad2/3 and inhibition of their nuclear translocation (Kretzschmar et al., 1999) . However, these studies employed highly transformed cell lines harboring additional mutations or deletions aside of expressing oncogenic Ras. Here we show that Smad nuclear translocation and transcriptional activation are normal in several epithelial cell lines expressing oncogenic Ras proteins. Rather, oncogenic Ras shifted p27 and CDK6 (but not CDK2) from the nucleus to the cytoplasm, and interfered with the TGF-b-mediated release of p27 from CDK6. Cytoplasmic p27 failed to associate with and to inhibit the nuclear CDK2 in response to TGF-b, suggesting that its mislocalization can block TGF-b anti-proliferative activity.
Results

Oncogenic Ras abrogates TGF-b-mediated growth inhibition
We have studied human N-Ras K61 , expressed in L20 cells (Mv1Lu mink lung epithelial cells expressing the murine ecotropic receptor) (Liu et al., 1997) were then isolated; the Ras4 and Ras10 clones were further characterized. Thymidine incorporation in the NRas K61 -expressing cells (Ras4, Ras10 and the original Ras-expressing cell pool) was hardly inhibited by TGFb1, in contrast to the strong inhibition (90% by 10 pM TGF-b1) in L20 cells (Figure 1a ). Analogous results (not shown) were obtained by counting cells after 5 days. As shown in Figure 1b , there was no high overexpression of Ras in Ras4 and Ras10 cells, and their total Ras levels were similar to that of the parental L20 cells. However, the cells expressing the constitutively active N-Ras K61 expressed 3 ± 4-fold more activated Ras than the L20 cells (Figure 1b) .
The speci®c Ras inhibitor S-trans,trans-farnesylthiosalicylic acid (FTS) inhibits Ras by displacing it from the cell membranes (Haklai et al., 1998; Niv et al., 1999) , and inhibits growth of Ras-dependent tumors in nude mice (Weisz et al., 1999) . FTS was highly eective in L20, Ras4 or Ras10 cells, reducing Ras levels by *90% within 24 h (Figure 1c ). This treatment restored growth inhibition by TGF-b in both Ras4 and Ras10 cells, while the growth inhibitory response to TGF-b in L20 cells was unaected (Figure 1d ). The ®nding that reducing the level of Ras leads to re-sensitization of the cells expressing constitutively active Ras to growth inhibition by TGF-b demonstrates that abrogation of TGF-b anti-proliferative activity by oncogenic Ras is not due to secondary genetic changes in these cells. Similarly, the proliferation of HepG2 cells that harbor oncogenic N-Ras (Hsu et al., 1993) was only weakly inhibited by TGF-b1, while FTS increased this inhibition from 20 ± 70%.
Translocation of Smad proteins to the nucleus is a key step in TGF-b signaling. This event was not aected by the expression of constitutively active Ras. Within 10 min of treatment with 10 pM TGF-b1, endogenous Smad2 and Smad3 (Smad2/3) accumulated in the nuclei of both the parental L20 cells and the NRas Oncogene p27 mislocalization by oncogenic Ras X Liu et al enon was also observed in transformed cells naturally expressing oncogenic N-Ras, such as HT1080 cells (from which we have cloned the N-Ras K61 employed in the present studies) and HepG2 cells (Figure 2a,b) . The rapid accumulation (80 ± 100% of the cells with predominantly nuclear Smad2/3 labeling within 10 min) was retained after prolonged incubation (6 h) with TGF-b1 (Figure 2b) .
To investigate whether the eect of N-Ras K61 on TGF-b responsiveness is related to inhibition of transcriptional responses, we examined several TGFb-responsive promoters in luciferase (Lux) reporter constructs. PE2.1 is a TGF-b-responsive fragment of the plasminogen activator inhibitor 1 (PAI-1) promoter that contains three Smad binding sites and one E box that binds the essential transcription factor TFE (Hua et al., 1998) . Activation of the PE2.1 promoter by TGF-b1, measured by the luciferase activity of the PE2.1-Lux construct, was as robust in Ras4 as in L20 cells (Figure 2c ). This also holds for the full-length PAI-1 reporter construct (Yamaguchi et al., 1995) , except that this reporter showed higher basal activity in N-Ras K61 -expressing cells ( Figure 2d ) due to the Rasinducible AP-1 responsive elements present in PAI-1 promoter (Keeton et al., 1991) . Analogous results were obtained using the luciferase constructs of the arti®cial promoters p3TP and p3TD (Figure 2d ), which contain three copies of a tetradecanoyl phorbol acetate responsive element (TRE) linked to a TGF-b-responsive segment of PAI-1 (Wieser et al., 1993) . Comparable transcriptional activation by TGF-b was also observed in HT1080 and HepG2 cells (not shown). The results in Figure 2 dier from a recent report (Kretzschmar et al., 1999) , which concluded that HRas V12 inhibits nuclear translocation of and transcriptional activation by Smad2/3. This may be due to: (i) the former study employed mainly highly transformed cells possibly harboring additional mutations, or high transient over-expression of oncogenic Ras (as opposed to the stable expression of oncogenic Ras at levels close to those of endogenous Ras in the current studies); (ii) the transcriptional response assay employed a promoter that requires co-expression of embryonic FAST-2, absent in non-embryonic epithelial cells. Indeed, studies on untransformed thyroid epithelial cells (Depoortere et al., 2000) showed that activation by EGF plus serum 
Effects of oncogenic Ras on cell-cycle regulating proteins
The above experiments demonstrate that oncogenic NRas does not perturb TGF-b-mediated nuclear translocation of Smad proteins and the ensuing transcriptional activation in the Mv1Lu L20 epithelial cells. The disruption of TGF-b anti-proliferative activity by oncogenic Ras in these cells must therefore occur further downstream in the TGF-b pathway. It has been reported that in Mv1Lu mink lung cells the induction of the p15 cell-cycle inhibitor and the concomitant release of p27 from cyclin D-CDK4/6 complexes play an important role in TGF-b-mediated growth arrest, by increasing the binding of p27 to CDK2 (Polyak et al., 1994; Reynisdottir and Massague, 1997; Reynisdottir et al., 1995; Tsubari et al., 1999) . As shown in Figure 3a ,b, there were no signi®cant dierences between L20 and Ras4 (or Ras10) cells in the induction of p15 by TGF-b or in the levels of CDK4, CDK6 and CDK2 (25 pM TGF-b1, 4 ± 8 h). A reduction in the level of CDK6 and CDK4 in L20 (Mv1Lu) cells (but much less in the N-Ras K61 -expressing cells) in response to TGF-b could be detected only after a longer exposure (15 ± 20 h) (Tsubari et al., 1999 , and data not shown). The basal p27 levels were also comparable between L20 and the Ras-expressing cells, and increased slightly (*1.2-fold) in response to TGF-b (25 pM, 4 ± 8 h) only in L20 cells (Figure 3b) .
We next examined the eects of TGF-b on the interactions between p27 and CDK4, CDK6 and CDK2. As depicted in Figure 3c , there was no alteration in the association of p27 with CDK4 upon incubation (up to 8 h) of L20 cells or N-Ras K61 -expressing cells with TGF-b1 (25 pM). In sharp contrast, exposure (4 or 8 h) to TGF-b mediated dissociation of p27 from CDK6 (2 ± 3-fold reduction) and elevated its association with CDK2 in the parental L20 cells (2 ± 3-fold increase; Figure 3c ). These ®ndings are in accord with the selective eect of TGF-b on CDK6 but not CDK4 levels in Mv1Lu cells (Tsubari et al., 1999) , although another study (Reynisdottir and Massague, 1997) detected TGF-b eects on both CDK6 and CDK4. The dierence may be due to higher TGF-b concentration and longer incubation employed in the latter study; however, it is apparent that under the current experimental conditions TGF-b mainly aected CDK6/p27 association. It should be noted that CDK6 and CDK4 do not respond identically in many systems, and there are several reports on selective eects on CDK6 (Sun et al., 1999a; Tsubari et al., 1999; Vlach et al., 1996) . Importantly, both the dissociation of p27 from CDK6 and its association with CDK2 were largely compromized in the N-Ras K61 -expressing cells (Figure 3c ). In both Ras4 and Ras10 cells, incubation with TGF-b did not signi®cantly release p27 from CDK6, and the level of p27 co-precipitated with CDK2 (which was three-fold lower in these cells prior to TGF-b addition) was only slightly increased (1.5-fold) and remained much lower (®ve-fold after 8 h) than in L20 cells (Figure 3c) . A signi®cant reduction in the faster migrating band of CDK2 (the active phosphorylated form; Reynisdottir et al., 1995) in L20 cells required longer incubation (15 h) with TGF-b (not shown). In addition, TGF-b1 elevated p15/CDK6 association in L20 but not in Ras4 or Ras10 cells (Figure 3c ).
Consistent with these observations, TGF-b inhibited CDK2 activity much more eectively in L20 cells (6 ± 10-fold) than in Ras4 or Ras10 cells (twofold; Figure  4a ). In these experiments, longer incubation (24 h) with TGF-b1 was employed to enhance the measured eect, /10 cm dish) were incubated with TGF-b1 (25 pM) for 0 ± 8 h. Poly(A) + mRNA was isolated using Oligotex (Qiagen), and the mRNA levels of p15 or actin (for normalization) were determined by an RNAase protection assay (Sun et al., 1999b) . (b) Immunoblotting (WB) of CDK4, CDK6, CDK2 and p27. Cells were plated in 10 cm dishes (10 6 /dish), grown for 3 days and treated with 25 pM TGF-b1 for the indicated times. After lysis (Sun et al., 1999b) , lysates (120 mg for CDK6, 50 mg for all other proteins) were subjected to SDS ± PAGE and immunoblotting using antibodies to CDK4 (goat SC-601, 1 : 1000), CDK6 (goat SC-177, 1 : 500), CDK2 (mouse SC-163, 1 : 2000) , (all from Santa Cruz Biotechnology) or p27 (mouse antibodies #25020, 1 : 2000, Transduction Laboratories). Visualization was by ECL, followed by densitometry (see Materials and methods). (c) Co-immunoprecipitation of p27 with CDK's. Cells were plated as in (b) and treated with 25 pM TGF-b1 for the indicated times. Lysates (200 mg protein) were subjected to immunoprecipitation (IP) with anti-CDK2, anti-CDK4, anti-CDK6 or anti-p15 (goat SC-612, Santa Cruz) antibodies (1 : 500 dilution) using protein A/G-sepharose (Sigma). After SDS ± PAGE, Western blotting was performed using anti-p27 or anti-CDK6. ECL and densitometry were as in (b). In all cases (a ± c), the data shown are representative of three independent experiments. In all the experiments, Ras4 and Ras10 cells yielded similar results
Oncogene p27 mislocalization by oncogenic Ras X Liu et al because the inhibition of CDK2 activity by p27 is not linear to its binding (detected only above a threshold level), and because the feedback loop connecting reduced cyclin E-CDK2 activity with reduced E2F release from pRb (Sherr and ampli®es the TGF-b inhibitory eect with time. Accordingly, TGF-b inhibited the transcriptional activity of E2F in L20 but not in the Ras-expressing cells, as measured using the pE2F-1-Lux luciferase reporter construct (Helin et al., 1992) (Figure 4b ).
Alteration of p27 and CDK6 localization by oncogenic Ras
The above results implicate p27/CDK6 and p27/CDK2 complexes as tentative targets for disruption of TGF-b growth inhibition by oncogenic N-Ras. We therefore examined the cellular localization of these proteins in L20 and N-Ras K61 -expressing cells. In epithelial cells such as Mv1Lu, p27 is mainly nuclear (Reynisdottir and Massague, 1997) . Figure 5 and Table 1 show that oncogenic N-Ras shifts p27 from the nucleus to the cytoplasm. This was seen with either HA-tagged p27 (HA-p27) in transiently transfected cells or with endogenous p27 in untransfected cells ( Figure 5 , Table  1 ), but not with the related cell cycle inhibitor p21 (data not shown). In either L20 or N-Ras K61 -expressing cells, the cellular localization of p27 was not aected by TGF-b ( Figure 5 and Table 1 ). Thus, while *80% of the L20 cells exhibited nuclear HA-p27, this percentage was much lower (14 ± 26%) in cells expressing oncogenic N-Ras. Qualitatively similar results were obtained for endogenous p27 (Figure 5b  Table 1 ). The only dierence was that the percentages of cells with nuclear p27 were smaller, due to the lower level of endogenous p27, allowing clear identi®cation of nuclear localization only in cells with high nuclear staining. To demonstrate that p27 mislocalization is mediated by constitutively active N-Ras and not by secondary mutations, we studied the eects of the Ras inhibitor FTS on p27 localization. FTS restored the nuclear localization of HA-p27 or p27 in all the cell lines examined (Figure 5a,b ) shifted HA-p27 to the cytoplasm in L20 cells (Figure 5c , Table 1 ). This suggests that p27 mislocalization is mediated by oncogenic Ras, and demonstrates that it can be induced not only by N-Ras K61 but also by other isoforms of oncogenic Ras proteins.
We next examined the subcellular localization of endogenous CDK6 and CDK2 in L20 and N-Ras K61 -expressing cells. While CDK2 was predominantly nuclear in essentially all of the cells in both L20 and Ras10 (or Ras4) cells, there were signi®cant dierences between these cells in the localization of CDK6 ( Figure  6 ). In L20 cells, CDK6 was predominantly nuclear in most of the cell population (80%), while expression of oncogenic N-Ras resulted in a dramatic reduction of nuclear CDK6 (30% nuclear). No such dierences were observed for CDK4, which exhibited both nuclear and cytoplasmic staining in all the cell lines examined (not shown). Incubation with TGF-b (even at 100 pM, 6 or 20 h) did not aect signi®cantly CDK6 localization (not shown). Treatment of N-Ras K61 -expressing cells with the Ras inhibitor FTS restored the nuclear localization of CDK6 (Figure 6a ; 80% and 70% in L20 and Ras10 cells, respectively), without aecting the Figure 6b). Thus, expression of N-Ras K61 shifts endogenous CDK6 from the nucleus to the cytoplasm concomitantly with p27. However, unlike the situation with endogenous CDK6, transiently overexpressed HA-CDK6 appeared both in the nucleus and the cytoplasm of either L20 or the NRas K61 -expressing cell lines (Figure 6c ). This observation is in line with the lack of a nuclear localization signal (NLS) in CDK6; in such a case, the cellular localization of CDK6 would be determined by association with other proteins, and overexpression of CDK6 alone would lead to loss of distinctive cellular localization.
Discussion
Transformed epithelial cells expressing oncogenic Ras often lose TGF-b-mediated growth inhibition (Filmus et al., 1992; Houck et al., 1989; Kretzschmar et al., 1999; Longstreet et al., 1992; Schwarz et al., 1988; Valverius et al., 1989) . The pathological relevance of this phenomenon is indicated by the accompanying increased metastasis in response to TGF-b (Oft et al., 1998 (Oft et al., , 1996 Yin et al., 1999) . How oncogenic Ras interferes with TGF-b-mediated growth arrest is still unclear; the disruption was proposed to occur at the level of Smad2/3 proteins (Kretzschmar et al., 1999) , but our results (Figure 2 ) demonstrate that this cannot be a general mechanism and that oncogenic Ras can disrupt TGF-b anti-proliferative activity without compromising the nuclear translocation and function of Smad proteins. The interference of oncogenic Ras with growth inhibition by TGF-b occurs at a later step (Figures 3 ± 6) , at the levels of the localization and interactions of CDK's and CDK inhibitor complexes known to be involved in cell cycle arrest by TGF-b (Polyak et al., 1994; Reynisdottir and Massague, 1997; Reynisdottir et al., 1995; Sherr and Roberts, 1999; Tsubari et al., 1999) . The disruption appears to be due to the lack of inhibition of CDK2 activity, mediated by mislocalization of p27 from the nucleus to the cytoplasm and by loss of TGF-b-induced partner switching of p27 from CDK6 to CDK2.
The anti-proliferative activity of TGF-b in Mv1Lu epithelial cells is mediated via induction of p15, which releases p27 from CDK4 or CDK6 and enables its binding to CDK2 (Polyak et al., 1994; Reynisdottir and Massague, 1997; Reynisdottir et al., 1995; Tsubari et al., 1999) . Figure 3 shows that the disruption of TGF-b signaling occurs downstream to the induction of p15. It is detected at the steps of TGF-b-mediated p27/CDK2 association (which is defective in the NRas K61 -expressing cells) and p27/CDK6 dissociation (which is compromised in these cells). Most importantly, p27 and CDK2 are co-localized in the nucleus of L20 cells but reside in dierent locations in N-Ras K61 -expressing cells (CDK2 remains nuclear, while p27 is cytosolic; Figures 5 and 6) . Thus, the failure of p27 to associate with CDK2 in cells expressing oncogenic Ras appears to be due to the sequestration of these proteins in dierent compartments. Accordingly, in these cells TGF-b failed to inhibit both CDK2 activity and E2F transcriptional activity (Figure 4 ) required for cell-cycle transition from G 1 to S (Sherr and .
There are numerous indications that cytoplasmic localization of p27 interferes with its activity as a growth inhibitor. In a variety of cells, a shift of p27 to the cytoplasm by dierent means (e.g., overexpression of c-Myc or of cyclin D3) largely reduced its ability to mediate growth arrest (Baldassarre et al., 1999; Vlach et al., 1996) . Using cells devoid of endogenous p27, it was possible to demonstrate that cytosolic p27 lacking its nuclear localization signal fails to induce growth arrest (Baldassarre et al., 1999) . However, in normal cells (including Mv1Lu epithelial cells) such a mutant can still inhibit growth, most likely by releasing endogenous p27 from CDK6 or CDK4 complexes (Reynisdottir and Massague, 1997 , and data not shown). Our ®ndings agree with the notion that loss of the nuclear localization of p27 disrupts its ability to inhibit cell growth. Even in the absence of TGF-b there was a signi®cantly lower level of p27/CDK2 complexes in the cells expressing oncogenic Ras (Figure 3 ), in accord with the dierent cellular localization of p27 and CDK2 in these cells (Figures 5 and 6 ) and with the failure of cytoplasmic p27 to mediate growth arrest.
CDK4 or CDK6 were proposed to act as a reservoir for p27 (Orend et al., 1998; Reynisdottir and Massague, 1997; Tsubari et al., 1999) , from which it can be released by p15 in response to TGF-b and mediate growth arrest by binding to CDK2. Because expression of oncogenic Ras shifts both endogenous p27 and CDK6 to the cytoplasm, it is possible that the primary eect of oncogenic Ras is on CDK6 localization, and association of p27 with CDK6 in this reservoir holds p27 in the cytoplasm. This possibility is ruled out by the ®nding that transiently overexpressed HA-p27 is also shifted to the cytoplasm in cells expressing oncogenic Ras (Figure 5 ). Since HA-p27 but not CDK6 is overexpressed in these cells, it follows that mislocalization of p27 by oncogenic Ras does not depend on association with CDK6. However, the loss of nuclear localization of overexpressed HA-CDK6 (Figure 6 ) suggests that its Ras-mediated shift to the cytoplasm depends on some limiting endogenous protein, possibly p27. The loss of TGF-b sensitivity in the CDK6/p27 reservoir upon expression of oncogenic Ras can disrupt TGF-b-mediated growth arrest at another step, by eliminating or reducing the release of p27 from this reservoir in response to TGF-b. This can reduce the amount of p27 available to bind to CDK2 even for residual CDK6/p27 complexes that may escape into the nucleus of the cells expressing oncogenic Ras. This disruption is further augmented by the failure of long incubations with TGF-b to reduce the CDK6 level in the L20-derived lines expressing oncogenic Ras, unlike the situation in the wild-type Mv1Lu L20 cells (Tsubari et al., 1999 , and data not shown). The two eects of oncogenic Ras (mislocalization of p27/CDK6 and the failure of TGF-b to release p27 from CDK6) may be related: it was shown in Mv1Lu epithelial cells that p15 prevents p27 binding only if it has prior access to cyclin D-CDK4/6 (Reynisdottir and Massague, 1997) . This would not occur in the cells that express oncogenic Ras, where the cytoplasmic co-localization Figure 5 Oncogenic Ras mediates mislocalization of p27 to the cytoplasm. (a) Localization of HA-p27. Cells in complete medium were preincubated with FTS (50 mM) in 0.1% DMSO or with DMSO (0.1%) alone for 48 h and transfected with HA-p27 (0.25 mg; see Materials and methods). After 18 h, they were incubated (6 h, 378C) with 100 pM TGF-b1. They were ®xed with 4% paraformaldehyde/0.2% Triton X-100, and processed for immuno¯uorescence. Labeling was by successive incubations with: (i) rabbit anti-HA (5 mg/ml); (ii) Cy3-goat anti-rabbit IgG (3 mg/ml). (b) FTS restores nuclear localization of endogenous p27 in Ras4 cells. Untransfected cells were treated as in (a). Labeling was with: (i) rabbit anti-p27 (1.25 mg/ml); (ii) biotinylated goat anti-rabbit IgG (5 mg/ml); (iii) Cy3-streptavidin (1.3 mg/ml). In both (a) and (b), Ras10 cells yielded similar results to Ras4 (not shown). (c) Mislocalization of p27 by transiently expressed oncogenic Ras. L20 Cells were co-transfected with HA-p27 (0.25 mg) and GFP-NRas V13 or GFP (1 mg) expression vectors (Materials and methods). After 18 h, they were treated with TGF-b1 (100 pM, 6 h) and processed for HA immuno¯uorescence as in (a). Arrow, a cell co-expressing HA-p27 (red) and GFP-N-Ras V13 (green). Arrowheads, cells expressing only HA-p27. Bars, 40 mm p27 mislocalization by oncogenic Ras X Liu et al of p27 and CDK6 enables their interaction prior to the induction of cytoplasmic p15 by TGF-b. In accord with this prediction, TGF-b elevated p15/CDK6 association in L20 but not in Ras4 or Ras10 cells (Figure 3c ). Finally, it should be noted that in view of the multiple eects of both Ras and TGF-b, which depend on the cellular context, it is possible that additional pathways exist for the disruption of TGF-b growth inhibition by oncogenic Ras. A plausible model for the abrogation of TGF-bmediated growth inhibition by oncogenic Ras involves the disruption of the TGF-b growth inhibitory response at two steps, which may be related. The ®rst is Ras-mediated mislocalization of p27 from the nucleus to the cytoplasm, which prevents p27 from interacting with the nuclear CDK2. The second is at the sensitivity of CDK6/p27 complexes to TGF-bmediated dissociation. This model and our results are consistent with the recent report that hepatocyte growth factor, which activates the Ras/MAP kinase pathway, restored CDK2 activity in Mv1Lu cells and released them from TGF-b-mediated growth arrest (Tsubari et al., 1999) . A recent study (Yang et al., 2000) reported that overexpressed HER-2/neu facilitated p27 degradation by mediating its mislocalization along with JAB1, an exporter of p27. However, JAB1 binding to p27 is not required for p27 mislocalization in the present study, since a mutated HA-p27 where the JAB1 binding domain (residues 97 ± 151; Tomoda et al., 1999) was deleted still localized to the cytoplasm in Ras4 and Ras10 cells (data not shown). Another possible mechanism could involve cyclin D, since forced overexpression of cyclin D3 was shown to contribute to cytoplasmic localization of p27 in some thyroid tumor cells (Baldassarre et al., 1999) . However, this possibility is unlikely in our case, since high overexpression of HA-p27 in transiently transfected Ras4 or Ras10 cells was still mislocalized to the cytoplasm, suggesting that its mislocalization does not depend on endogenous cellular components whose levels are much lower. Thus, the details of the molecular mechanism by which constitutively active Ras causes p27 mislocalization are still unclear, and require further studies. The importance of the eects of Ras on TGF-b-mediated growth inhibition is underscored by the high incidence of oncogenic Ras in human tumors (Bos, 1989) and by the correlation between low p27 levels or extranuclear p27 localization and tumor aggression (Catzavelos et al., 1999; Loda et al., 1997; Singh et al., 1998) . The realization that Ras inhibitors such as FTS can restore the growth inhibitory response of epithelial cells to TGF-b suggests that this combination may be exploited in the therapy of certain epithelial tumors.
Materials and methods
DNA constructs, transfection and infection
Human N-Ras K61 was cloned by a genetic screen for suppressors of TGF-b signaling using a cDNA library from HT1080 cells (Hua et al., 1998) , and subcloned into the bicistronic retroviral vector pMX-IRES-GFP1.1 (Liu et al., 1997) ; details of the cloning will be published elsewhere. Production of retroviruses expressing N-Ras K61 , infection of L20 cells and FACS sorting were described (Liu et al., 1997) . Transient transfections with other vectors employed Fugene 6 (Roche Chemicals). Vectors employed for transient transfections include pEGFP-C3 (Clontech); GFP-K-Ras V12 in pEGFP-C3 (Niv et al., 1999) ; GFP-N-Ras V13 and GFP-HRas V12 in the same vector; HA-p27 in pCG-N-BL, provided by Dr J Kato (Tomoda et al., 1999); and HA-CDK6 in pCMV (van den Heuvel and Harlow, 1993) .
Tissue culture and transcriptional activation assays
Growth conditions for Mv1Lu-derived lines (Liu et al., 1997) , HT1080 and HepG2 cells (Hua et al., 1998) were described. Transcriptional activation was measured by the luciferase assay (Hua et al., 1998) after transfection with pE2.1-Lux (Hua et al., 1998) , PAI-1-Lux (Yamaguchi et al., 1995) , p3TP-Lux and p3TD-Lux (Wieser et al., 1993) , or pE2F-1-Lux (Helin et al., 1992) . pCMV-bgal (Clontech) was included in each sample, and the b-galactosidase activity was used to normalize for transfection eciency (Hua et al., 1998) . Transfections were performed on 2610 5 cells with 0.75 mg luciferase construct DNA and 0.5 mg pCMV-bgal. After incubation with or without TGF-b1 (24 h, 100 pM), luciferase activity was determined using the luciferase assay system (Promega) and b-galactosidase activity was measured using a luminescence detection kit (Clontech).
